Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced
Portfolio Pulse from
The National Institutes of Health's NIAID announced interim results from the STOMP study, indicating that SIGA's antiviral treatment, tecovirimat, did not show efficacy in treating mild to moderate mpox. Consequently, the study's DSMB recommended halting patient enrollment in the study's randomized arms.
December 10, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SIGA's tecovirimat did not demonstrate efficacy in treating mild to moderate mpox in the STOMP study, leading to a halt in patient enrollment in the study's randomized arms.
The interim results from the STOMP study showed that SIGA's tecovirimat was not effective in resolving skin and mucosal lesions in mpox patients, leading to a recommendation to stop patient enrollment. This negative outcome is likely to impact SIGA's stock negatively in the short term as it affects the perceived effectiveness of one of their key products.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100